ESEric A. F. Simoes

Eric A. F. Simoes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eric A. F. Simoes has a total of 260 co-authors. Here are the top co-authors by number of shared publications:

  • Phyllis Carosone-Link

    Department of Pediatrics, Children's Hospital Colorado, Aurora, CO, USA; Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA

    7 shared publications
  • Rowena Crow

    University of Colorado School of Medicine, Aurora, USA

    4 shared publications
  • Cissy B. Kartasasmita

    Medicine Padjadjaran University/Hasan Sadikin General Hospital, Bandung, Indonesia

    3 shared publications
  • Martin Lloyd Hibberd

    Department of Infection Biology, London School of Hygiene & Tropical Medicine, London, UK

    3 shared publications
  • Sameer Palaskar

    Tahsil: Dharni, Mahatma Gandhi Tribal Hospital, MAHAN Trust, Karmgram, India

    3 shared publications
  • Vibhawari Dani

    Tahsil: Dharni, Mahatma Gandhi Tribal Hospital, MAHAN Trust, Karmgram, India

    3 shared publications

Latest Publications

  • Open Access

    Respiratory Syncytial Virus and Human Metapneumovirus Respiratory Hospitalizations and Outcomes in Colorado Adults ≥50 Years of Age: 2016-2023.

    by Eric A F Simões, Robert J Suss, Dhananjay Raje

    Among older adults, respiratory syncytial virus (RSV) infection is a known cause of hospitalization, intensive care unit (ICU) admission, and mortality risk. The severity of the disease burden of human metapneumovirus (HMPV) among older adults is less well recognized. The objective of this study was to better understand risk factors for hospitalization with and outcomes in adults ≥50 years of age infected with HMPV and to compare these with RSV risk factors and outcomes. This was a retrospective cohort analysis of adults 50-88 years of age in 93 medical facilities in the Colorado Hospital Association database between 2016 and 2023. RSV and HMPV, other respiratory infections, and comorbidities were identified using International Classification of Diseases, Tenth Revision codes and grouped by increasing numbers of comorbidities. Multivariate logistic regression was performed to estimate the risk of the various predictors on ICU admission, and mortality for both HMPV and RSV infection, adjusted for sex, age, and comorbidity. The highest risk for ICU admission was chronic obstructive pulmonary disease (COPD) (RSV: adjusted odds ratio [aOR], 2.24 [95% confidence interval {CI}, 1.81-2.77], P < .001; HMPV: aOR, 2.99 [95% CI, 2.13-4.19], P < .001), and those with neuromuscular disease without dementia (RSV: aOR, 2.33 [95% CI, 1.98-2.75], P < .001; HMPV: aOR, 2.22 [95% CI, 1.75-2.80], P < .001). Age significantly increased the odds of mortality among RSV-infected but not HMPV-infected patients. Neurological disorders with dementia were the highest comorbid risk factor for RSV mortality (aOR, 4.16 [95% CI, 3.01-5.77]; P < .001), in contrast to COPD for HMPV mortality (aOR, 12.44 [95% CI, 3.02-51.17]; P < .001). HMPV infection poses a unique disease burden with specific high-risk comorbidities among the older adult population distinct from that of RSV and warrants further study.


  • Open Access

    A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants

    by Shabir A Madhi, Eric A F Simões, Armando Acevedo, Jose M Novoa Pizarro, Julie S Shepard, Radha A Railkar, Xin Cao, Brian M Maas, Xiaowei Zang, Andrea Krick, et al.

    Background: Clesrovimab is an investigational monoclonal antibody with an extended half-life targeting site IV of the respiratory syncytial virus (RSV) fusion protein for the prevention of RSV disease in infants. Methods: In this phase 1b/2a, double-blind study, 183 healthy preterm and full-term infants 2 weeks to 8 months of age were randomized 4:1 within 5 panels (preterm 20, 50, 75, or 100 mg; full-term 100 mg) to receive 1 dose of clesrovimab or placebo. The objectives were to evaluate safety, pharmacokinetics, serum neutralizing antibodies (SNA), and antidrug antibodies (ADA). The incidence of RSV-associated end points (medically attended lower respiratory tract infection, hospitalization, and acute respiratory infection) were also evaluated through 150 days postdose. Results: The most common adverse event through day 14 was irritability; no treatment-related serious AEs were reported. Clesrovimab serum concentrations displayed a geometric mean apparent half-life of 44.9 days. Of participants receiving clesrovimab, 51 (36.7%) developed ADA with no apparent impact in pharmacokinetics. SNA titers increased in a dose-dependent manner at day 150. The incidences of RSV-associated end points were lower in infants treated with clesrovimab compared with placebo. Conclusions: Clesrovimab was generally well tolerated and exhibited an extended half-life compared to typical IgG1 antibodies, supporting its ongoing development in late-stage trials. Clinical Trial Registration. NCT03524118.


  • Open Access

    Locally Prepared Therapeutic Food for Treatment of Severely Underweight Children in Rural India: An Interventional Prospective Controlled Community-Based Study with Long Follow-Up:—‘SAMMAN’ Trial

    by Ashish Rambhau Satav, Vibhawari S. Dani, Jayashri S. Pendharkar, Kavita Ashish Satav, Dhananjay Raje, Dipty Jain, Shubhada S. Khirwadkar, Eric A. F. Simões

    Background: Severely underweight (SUW) children contribute significantly to under-five mortality and morbidity. There are WHO guidelines for the management of severe acute malnutrition but no specific guidelines for SUW management. Objective: The objectives were to achieve a recovery rate of 30% at 90 days of treatment for severe underweight (SUW) children aged 6–60 months, compare changes in weight-for-age Z (WAZ) scores, growth patterns, and case fatality rates between intervention and reference arms (RA), and reduce the prevalence of SUW in the intervention arm (IA). The target of a 30% recovery rate was achievable and significant based on our past research conducted in similar settings. Methods: Design: A prospective controlled community-based, longitudinal, two arms (IA, RA), intervention study with long follow-up was conducted between January 2011 and October 2023. Setting: Primary care for participants from 14 villages in rural Melghat, India. Participants: The study participants included SUW children aged 6–60 months and age-matched (±2 weeks) normal controls. The SAMMAN (Acronym for SAM-Management) intervention was comprised of local therapeutic food-micronutrient (LTF-MN) therapy for 90 days, intensive behavior change communication, infection treatment, and quarterly anthropometric records. SUW recovery, growth patterns, case fatality rate, prevalence at 90 days of therapy and at 60 months of age, and survival until early adolescence were assessed. ANCOVA analysis was used to obtain changes in Z-scores. Results: In the IA, the recovery rate was 36.8% at 90 days and 78.2% at 60 months of age. The mean difference in change in WAZ scores between the intervention arm and the reference arm was statistically significant (p < 0.0001). Growth patterns were similar between the two arms up to early adolescence. The SUW case fatality rate was significantly lower in the IA (0.9%) as compared to 4.62% in the RA at 60 months (p = 0.022). The reduction in SUW prevalence in intervention villages was higher than in the control villages (p < 0.001). The cost of management per SUW child was 3888 INR (47 USD) less than RUTF. Conclusion: The SAMMAN intervention is safe and cost-effective for significantly improving WAZ scores, sustainable, and hence replicable in resource-limited areas.


  • Open Access

    Comparison of measles plaque reduction neutralization test (PRNT) and measles virus-specific IgG ELISA for assessment of immunogenicity of measles-mumps-rubella vaccination at 5–7 months of age and maternal measles antibodies

    by Dorthe Maria Vittrup, Andreas Jensen, Michelle Malon, Anne Cathrine Zimakoff, Jesper Kiehn Sørensen, Brickley Littell, Eric A.F. Simões, Jannet Svensson, Lone Graff Stensballe


  • Open Access

    Respiratory Syncytial Virus Hospital-Based Burden of Disease in Children Younger Than 5 Years, 2015-2022

    by Robert J. Suss, Eric A. F. Simões

    Studies outside the US in the post–COVID-19 pandemic period (ie, 2020 to the present) have demonstrated a shift in epidemiologic characteristics of the respiratory syncytial virus (RSV) season. For example, delayed RSV seasons have been observed in France,1,2 Germany,3 Finland,4 Israel,5 and England,6 as well as in the Southern Hemisphere, including in Argentina,7 South Africa,8 and Australia.9,10 In 1 study, a delayed onset of the first postpandemic RSV season was reported in 11 countries, including South Korea, Canada, Chile, Brazil, and the US, among others.11 Nonpharmaceutical interventions (NPIs) are generally attributed internationally for the delayed RSV resurgences.1,4,9,10,12-17


  • Open Access

    Etiology of Acute Lower Respiratory Illness Hospitalizations Among Infants in 4 Countries

    by John Kubale, Stephanie Kujawski, Irena Chen, Zhenke Wu, Ilham Abu Khader, Iris Hasibra, Brett Whitaker, Lionel Gresh, Artan Simaku, Eric A F Simões, et al.

    Background: Recent studies explored which pathogens drive the global burden of pneumonia hospitalizations among young children. However, the etiology of broader acute lower respiratory tract infections (ALRIs) remains unclear. Methods: Using a multicountry study (Albania, Jordan, Nicaragua, and the Philippines) of hospitalized infants and non-ill community controls between 2015 and 2017, we assessed the prevalence and severity of viral infections and coinfections. We also estimated the proportion of ALRI hospitalizations caused by 21 respiratory pathogens identified via multiplex real-time reverse transcription polymerase chain reaction with bayesian nested partially latent class models. Results: An overall 3632 hospitalized infants and 1068 non-ill community controls participated in the study and had specimens tested. Among hospitalized infants, 1743 (48.0%) met the ALRI case definition for the etiology analysis. After accounting for the prevalence in non-ill controls, respiratory syncytial virus (RSV) was responsible for the largest proportion of ALRI hospitalizations, although the magnitude varied across sites—ranging from 65.2% (95% credible interval, 46.3%–79.6%) in Albania to 34.9% (95% credible interval, 20.0%–49.0%) in the Philippines. While the fraction of ALRI hospitalizations caused by RSV decreased as age increased, it remained the greatest driver. After RSV, rhinovirus/enterovirus (range, 13.4%–27.1%) and human metapneumovirus (range, 6.3%–12.0%) were the next-highest contributors to ALRI hospitalizations. Conclusions: We observed substantial numbers of ALRI hospitalizations, with RSV as the largest source, particularly in infants aged <3 months. This underscores the potential for vaccines and long-lasting monoclonal antibodies on the horizon to reduce the burden of ALRI in infants worldwide.


  • Open Access

    Community—Minimal Invasive Tissue Sampling (cMITS) using a modified ambulance for ascertaining the cause of death: A novel approach piloted in a remote inaccessible rural area in India

    by Ashish Satav, Niteen Wairagkar, Shubhada Khirwadkar, Vibhawari Dani, Reeta Rasaily, Usha Agrawal, Yagnesh Thakar, Dhananjay Raje, Fouzia Siraj, Pradyot Garge, et al.

    Melghat in India is a hilly, forested, difficult to access, impoverished rural area in northeast part of Maharashtra (Central India) with difficult healthcare access. Melghat has very high Mortality rates, because of grossly inadequate medical facilities. (1) Home deaths contribute to 67% of deaths,(2) which are difficult to track and where cause of death is mostly unknown. A feasibility study was carried out in 93 rural villages and 5 hospitals to assess feasibility of tracking real-time community mortality and to ascertain cause of death in 0–60 months and 16–60 years age group using Minimal Invasive Tissue Sampling (MITS) in purpose-modified ambulance. We used the network of village health workers (VHW)s, to establish real-time community mortality tracking. Upon receipt of reports of home death, we performed MITS within 4 h of death in the vicinity of the village. We conducted 16 MITS. Nine, in MITS ambulance in community and seven at MAHAN hospital. The acceptance rate of MITS was 59.26%. Standard operating procedure (SOP) of conducting community MITS in an ambulance, is established. Major challenges were, Covid19 lockdown, reluctance of tribal parents for consent for MITS due to illiteracy, superstitions and fear of organ removal. Ambulance was an easy to reach transport means in remote area, provided a well-designed and discrete facility to perform MITS in community, winning the confidence of bereaved family. This has reduced time interval between time of death and performing MITS. MITS in purpose-modified Ambulance can be used worldwide for community MITS especially in areas which are remote and lack healthcare access. This solution needs to be assessed in different cultural settings to document culture specific issues.


  • Open Access

    Elevated serum IgA following vaccination against SARS-CoV-2 in a cohort of high-risk first responders

    by Brian T. Montague, Matthew F. Wipperman, Erica Chio, Rowena Crow, Andrea T. Hooper, Meagan P. O’bRien, Eric A. F. Simões

    IgA plays an important early neutralizing role after SARS-CoV-2 infection. Systemically administered vaccines typically produce an IgM/IgG predominant response. We evaluated the serum anti-spike (anti-S) IgG, anti-nucleocapsid (anti-N) IgG and anti-S IgA response following vaccination against SARS-CoV-2 in a cohort of first-responders. Among the 378 completely vaccinated participants, 98% were positive for anti-S IgG and 96% were positive for anti-S IgA. Nine percent were positive for anti-N IgG suggesting prior exposure to SARS-CoV-2. No statistically significant difference was seen in IgA response based on prior evidence infection (p = 0.18). Ninety-eight of those receiving the Moderna vaccine (98%) were positive for anti-S IgA as compared to 91% of those who received the Pfizer vaccine (p = 0.0009). The high proportion of participants observed to have a positive anti-S IgA response after vaccination suggests that the vaccines elicit a systemic response characterized by elevated levels of both IgG and IgA.